Overview

Fluphenazine Decanoate for Psoriasis

Status:
Terminated
Trial end date:
2008-09-01
Target enrollment:
Participant gender:
Summary
We are doing this research study to evaluate the effectiveness and safety of fluphenazine decanoate when injected with a needle into psoriasis lesions in adults. Fluphenazine decanoate is FDA (U.S. Food and Drug Administration) approved for use in people who have schizophrenia and psychotic symptoms. Fluphenazine decanoate is not approved by the FDA for use in psoriasis. Fluphenazine decanoate slows T cell growth in cells in laboratory test tubes. Its usefulness and safety in people with psoriasis will be investigated in this study.
Phase:
Phase 2
Details
Lead Sponsor:
Tufts Medical Center
Collaborator:
Immune Control
Treatments:
Decanoic acid
Fluphenazine
Fluphenazine depot
Fluphenazine enanthate